Bio‑Rad posts flat Q2 revenue

Bio-Rad Laboratories reported second-quarter revenue of $651.0 million on August 4, little changed from $651.6 million a year earlier, with gains in Clinical Diagnostics offset by weaker Life Science sales. (investors.bio-rad.com) That mix matters because Bio-Rad sells into two different markets. Clinical Diagnostics is tied to hospital and lab testing demand, while Life Science is more exposed to research spending by universities, government labs and biotech customers. (investors.bio-rad.com) The company’s own explanation was direct. Chief Executive Norman Schwartz said “growth in Clinical Diagnostics” was offset by “continued softness in Life Science,” and Bio-Rad said the Life Science decline was primarily driven by ongoing challenges in the academic research market. (investors.bio-rad.com) ### Where did the quarter actually weaken? Life Science net sales were $252.0 million in the quarter ended June 30, down 4.1% from a year earlier, or down 5.1% on a currency-neutral basis. (investors.bio-rad.com) Bio-Rad said that drop was primarily driven by academic research demand. The earnings call added more detail on where that pressure showed up. Bio-Rad said academic and government demand remained below historical levels, particularly in the Americas, even as some conditions improved toward the end of the quarter. (investors.bio-rad.com) That makes the result less about a one-off product issue than about end-market demand. Bio-Rad tied the weakness to research customers rather than to pricing, a recall or a manufacturing disruption. (investors.bio-rad.com) ### What held up inside the business? Clinical Diagnostics net sales were $399.0 million, up 2.6% from the same quarter in 2025, or up 0.3% on a currency-neutral basis. That segment was enough to keep total company revenue roughly flat. (investors.bio-rad.com) Digital PCR was another bright spot. Schwartz said digital PCR instrument revenue grew more than 20%, while call summaries said total digital PCR revenue rose 6% on a currency-neutral basis. (news.alphastreet.com) EMEA also returned to growth, according to Schwartz, helped by Middle East channel restocking during what he described as continued regional volatility. (investors.bio-rad.com) ### Did profit and cash flow move with sales? Bio-Rad reported GAAP net income of $371.4 million, up from $317.8 million a year earlier, and diluted earnings per share of $13.85 versus $11.67. On a non-GAAP basis, diluted earnings per share were $2.62, compared with $2.61 a year earlier. (investors.bio-rad.com) Operating cash flow was $98.7 million in the quarter, down from $116.5 million a year earlier. Schwartz also said Bio-Rad repurchased about $32 million of shares during the period. (investors.bio-rad.com) Gross margin was 53.1%, compared with 53.0% a year earlier, while income from operations fell to $72.6 million from $77.1 million. (investors.bio-rad.com) ### What does management say about the rest of 2026? Bio-Rad said on August 4 that it was reaffirming its full-year outlook. The company has previously pointed investors to 2026 currency-neutral revenue growth in a range of negative 3% to positive 0.5%. (investors.bio-rad.com) Management also said several end markets remain in transition, according to earnings-call summaries, while the company continues operational changes aimed at improving agility and competitiveness. (investors.bio-rad.com) The next formal checkpoint will come with Bio-Rad’s third-quarter reporting cycle, which investors can follow through the company’s investor-relations site, press releases and SEC filings. (investors.bio-rad.com) (marketbeat.com) (investors.bio-rad.com)